All In Biotech

Drug Trial Radar · NCT00143286

A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation

A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline ( CP-526,555) for the Maintenance of Smoking Cessation

Last checked: Nov 19, 2026Latest source record: Jun 4, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,000

Actual

Start

Apr 2003

Primary completion

Not stated

Study completion Mar 2005

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 2, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.

Conditions

  • Smoking Cessation

Interventions

  • varenicline (CP-526,555)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Continuous abstinence Weeks 13 -24.

Locations

24 sites in 7 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Santa Ana, California

  • Pfizer Investigational Site

    West Palm Beach, Florida

  • Pfizer Investigational Site

    Lexington, Kentucky

  • Pfizer Investigational Site

    Mogadore, Ohio

  • Pfizer Investigational Site

    Dallas, Texas

  • Pfizer Investigational Site

    Seattle, Washington

  • Pfizer Investigational Site

    Calgary, Alberta, Canada

  • Pfizer Investigational Site

    Halifax, Nova Scotia, Canada

  • Pfizer Investigational Site

    Ottawa, Ontario, Canada

  • Pfizer Investigational Site

    Toronto, Ontario, Canada

  • Pfizer Investigational Site

    Cornwall, Prince Edward Island, Canada

  • Pfizer Investigational Site

    Sherbrooke, Quebec, Canada

  • Pfizer Investigational Site

    Prague, Czechia

  • Pfizer Investigational Site

    Aarhus C, Denmark

  • Pfizer Investigational Site

    Frederikssund, Denmark

  • Pfizer Investigational Site

    Hellerup, Copenhagen, Denmark

  • Pfizer Investigational Site

    Bergen, Norway

  • Pfizer Investigational Site

    Hønefoss, Norway

  • Pfizer Investigational Site

    Oslo, Norway

  • Pfizer Investigational Site

    Gothenburg, Sweden

  • Pfizer Investigational Site

    Helsingborg, Sweden

  • Pfizer Investigational Site

    Stockholm, Sweden

  • Pfizer Investigational Site

    London, United Kingdom

  • Pfizer Investigational Site

    London, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.